Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib

Martin Sedlacek, Jason R. Pettus

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

A 67-year-old woman with transverse myelitis and seizure disorder secondary to suspected central nervous system (CNS) systemic lupus erythematosus (SLE) and seropositive rheumatoid arthritis had two episodes of severe nephrotic syndrome 15 years apart. She underwent a renal biopsy in both episodes, showing tip lesion variant focal segmental glomerulosclerosis (FSGS). The patient responded both times to prednisone treatment, achieving a complete remission within 2 months in the first episode and remission 4 months in the second episode. A year after her second episode, the patient had a third episode of severe nephrotic syndrome. She achieved an equally rapid complete remission in 3 months without steroid treatment, as she was concomitantly treated with the Janus Kinase (JAK) inhibitor tofacitinib for a flare of rheumatoid arthritis. This case report suggests that JAK inhibitors may have therapeutic use in FSGS, which is supported by experimental data in the medical literature.

Original languageEnglish
Pages (from-to)225-230
Number of pages6
JournalCEN Case Reports
Volume11
Issue number2
DOIs
StatePublished - 1 May 2022

Keywords

  • Complete remission
  • FSGS
  • JAK inhibitor
  • Rhupus
  • Tip lesion variant
  • Tofacitinib

Fingerprint

Dive into the research topics of 'Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib'. Together they form a unique fingerprint.

Cite this